Office of Research
Clinical Trials

Higher Dose Radiation Therapy for Advanced Pancreatic Cancer Trial

This study is exploring if giving higher doses of radiation can help people with advanced pancreatic cancer live longer. Participants must have already undergone 4-6 months of chemotherapy and have stable disease without progression. There are two groups in the study. One group will receive standard treatment, which could include continuing chemotherapy, a normal dose of radiation, or observation. The other group will receive higher doses of radiation over a shorter period to see if it prolongs their survival. Patients will have regular follow-ups and will be checked through blood tests, imaging scans, and tissue biopsies. They are monitored over a period that includes every three-month checkups for two years and then yearly for another three years. This study aims to not only see if survival improves but examine side effects, quality of life, and any changes in disease progression.

This study may be appropriate for those with: Metastatic Cancer

Testing New Treatment for Residual Cancer in B-cell Lymphoma Patients

This study is testing if a new experimental treatment named cemacabtagene ansegedleucel (or cema-cel for short) can help adults with large B-cell lymphoma, a type of blood cancer. Patients who have already finished one round of regular treatment and are still showing signs of leftover cancer according to a special test are being looked at. The study compares cema-cel treatment versus just watching the patients to see which helps more in preventing cancer events and eliminating leftover cancer cells. Participants must have completed standard initial therapy, be over 18, and meet certain health criteria. Those with recent other cancers or serious current infections, among other things, cannot join. The study will check for various outcomes over several months to see how well cema-cel works and note any side effects.

This study may be appropriate for those with: Newly Diagnosed Cancer

Monitoring in Breast Cancer- ctDNA

This study follows people with breast cancer over time to see whether tiny amounts of cancer DNA in the blood (called circulating tumor DNA or ctDNA) can show if cancer remains after treatment and predict if it will come back. Participants give blood samples at different times: during pre-surgery treatment, after surgery, during routine follow-up, and up to long-term monitoring. The study includes patients receiving pre-surgery treatment, those who have completed surgery and have no visible disease, and people who have been disease-free for five years but were originally at higher risk. Researchers will use DNA sequencing of the blood to look for signs of minimal residual disease (MRD). The main goal is to compare disease-free survival between people with and without detectable ctDNA. Secondary goals examine distant recurrence, overall survival, how MRD relates to tumor response after surgery, and how long it takes from a first positive ctDNA test to clinical recurrence. The study is observational - it only collects samples and clinical information - and aims to improve early detection of recurrence and help guide future tests and treatments.

Study of Ipatasertib with Chemoradiation for Head and Neck Cancer

This study is testing if a new drug, ipatasertib, can improve treatment when added to the usual chemotherapy and radiation for advanced head and neck cancer. Ipatasertib could help stop cancer growth by targeting specific proteins in cancer cells. The study aims to find the best dosage alongside existing treatments. It's primarily for patients with advanced stages of head and neck squamous cell carcinoma. Participants must be 18 or older, able to swallow pills, and meet certain health criteria. The study examines safety, necessary dosage, and treatment effectiveness. Patients will receive ipatasertib and typical cancer treatments over a set schedule and undergo various imaging tests. After treatment, they'll be monitored periodically up to two years. This research hopes to improve survival rates and better control cancer growth through this novel treatment combination.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study on BAY 2927088 for Lung Cancer with HER2 Mutations

This study is examining a new treatment called BAY 2927088 for people with advanced non-small cell lung cancer (NSCLC) that involves specific changes in the HER2 gene. The goal is to see how well this drug works compared to standard chemotherapy. Participants will receive either the new medication orally or standard chemotherapy via infusions. Doctors will use imaging tests like CT and MRI scans to track cancer progress, along with various health tests. The study aims to observe progression-free survival and overall survival rates, and assess safety through the observation of side effects and adverse reactions.

This study may be appropriate for those with: Metastatic Cancer

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.

This study may be appropriate for those with: Metastatic Cancer

Neladalkib vs Alectinib in ALK NSCLC

This is a global Phase 3 study that will randomly assign people with ALK-positive advanced non-small cell lung cancer (who have not had prior systemic treatment for their lung cancer) to one of two first-line treatments: neladalkib (NVL-655) or alectinib. About 450 participants will be split evenly between the two drugs. The main goal is to see which drug keeps the cancer from getting worse for a longer time, using independent radiology review. Other goals include overall survival, brain (intracranial) outcomes, tumor response rates, safety and side effects, and patient-reported quality of life. Treatment continues until the cancer progresses or side effects prevent further treatment. Participants will be followed with regular scans and visits, and some measures will be collected for up to five years after the first patient is dosed.

This study may be appropriate for those with: Metastatic Cancer

HNSCC Longitudinal Multiomic Study

This is a non‑interventional, forward‑looking study that will collect blood and tumor tissue from adults with metastatic or unresectable recurrent head and neck squamous cell carcinoma who are starting first‑line anti‑PD‑1 or anti‑PD‑L1 therapy as part of usual care. Samples will be tested using next‑generation sequencing (NGS), circulating tumor DNA (ctDNA) assays, RNA and immune profiling, and other multiomic techniques. Collections occur at baseline and at multiple time points during treatment and follow up. The goal is to find biomarkers that help predict who will benefit from treatment, understand how cancers become resistant, and link biomarker changes to real‑world outcomes like survival and time to next treatment. Participants are followed for up to five years; no experimental treatments are provided as part of the study.

This study may be appropriate for those with: Metastatic Cancer

Testing a New Combo Therapy for Relapsed Aggressive B-cell Lymphoma

This trial studies how well a combination of drugs called ViPOR works for patients with a type of aggressive lymphoma that has returned after treatment or not responded to previous treatments. ViPOR combines 5 drugs: venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid. Each has its own function, but together they aim to stop cancer cells from growing by targeting specific proteins and supporting the immune system's ability to attack these cancer cells. This research will see whether this drug mix can help the patient's lymphoma disappear fully and track patients' survival over time. Participants will receive these medicines in cycles every 21 days for up to 6 cycles and might have tests like blood tests and scans along the way. The study checks if this treatment stops the lymphoma from growing and how safe it is.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Study on Heated Chemotherapy and Niraparib for Advanced Ovarian Cancer

This study is testing a new method of chemotherapy for treating advanced ovarian, primary peritoneal, and fallopian tube cancers. Researchers are comparing two groups: one receiving heated chemotherapy (HIPEC) with cisplatin during surgery and the other not receiving HIPEC. Both groups will receive additional standard chemotherapy post-surgery followed by a medication called niraparib. The study aims to see if this heated chemotherapy method helps people stay cancer-free for longer. It's targeted at patients with stage III or IV of these specific cancers who have completed standard neoadjuvant therapy and are ready for surgery. The study measures progression-free survival as its main outcome.

This study may be appropriate for those with: Newly Diagnosed Cancer

Phase 2 Study of ACR-368 in Endometrial Cancer

This Phase 2 study tests ACR-368 in people with high-grade endometrial cancer. Participants are placed into one of three groups. Arms 1 and 2 use a lab test called OncoSignature to predict sensitivity to ACR-368: Arm 1 (OncoSignature Positive) receives ACR-368 alone; Arm 2 (OncoSignature Negative) receives ACR-368 plus ultra-low dose gemcitabine (ULDG). Arm 3 (no OncoSignature testing) also receives ACR-368 with ULDG; EU sites enroll only to Arm 3. Treatment continues until the cancer gets worse, side effects become unacceptable, or the person stops. The main goal is to measure tumor response by CT or MRI every 8 weeks for up to 2 years. Safety, some drug levels in blood, overall survival, time without cancer growth, and duration of any response are also tracked. Key eligibility includes prior platinum chemotherapy and prior anti-PD-(L)1 therapy, measurable disease, and adequate overall health. Certain conditions like uncontrolled viral infections, serious heart disease, recent major surgery or recent cancer treatment, symptomatic brain metastases on high-dose steroids, bowel obstruction, or prior CHK1 inhibitor use will exclude people from joining.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Pasritamig With Docetaxel Study

This phase 3 trial tests whether adding pasritamig to standard chemotherapy (docetaxel) helps men with metastatic castration resistant prostate cancer live longer without their disease getting worse on scans. Eligible men must have prostate adenocarcinoma that has spread, be on hormone lowering treatment or surgically castrated, have had at least one prior androgen receptor targeted therapy, and be in generally good health for cancer treatment. Participants are randomly assigned to receive pasritamig plus docetaxel or docetaxel alone. Doctors will use imaging scans to track when the cancer progresses, and will also measure overall survival, pain and quality of life, PSA blood changes, need for more treatment, bone related problems, tumor response if measurable, and side effects. Blood tests, scans, and questionnaires are used during treatment and for follow up. The main question is whether the combination delays radiographic progression compared with chemotherapy alone.

This study may be appropriate for those with: Metastatic Cancer

Radiation With Cetuximab or Chemotherapy

This phase 3 trial compares two treatments given with high-precision radiation therapy (IMRT) for people with advanced head and neck cancer who cannot take cisplatin. Patients are randomly placed into one of two groups. One group gets weekly cetuximab (a drug that targets the EGFR protein on some cancer cells) together with 35 daily radiation treatments over about 7 weeks. The other group gets weekly carboplatin and paclitaxel chemotherapy together with the same radiation schedule. Patients have scans and blood tests during the study and are followed after treatment at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months and then yearly. The main goal is to compare progression-free survival between the two groups. Secondary goals include comparing overall survival, side effects, where the cancer returns if it does, and changes in eating and speaking function.

This study may be appropriate for those with: Metastatic Cancer

Bladder Preservation Immunoradiation

This Phase II study tests whether combining the immune drug pembrolizumab with radiation therapy can allow people with muscle invasive bladder cancer to keep their bladder after the tumor has already shrunk from pre-surgery chemotherapy. Eligible patients have an excellent clinical response after neoadjuvant chemotherapy and will receive daily photon radiation to the bladder Monday through Friday for up to about 4 weeks while also getting pembrolizumab through an IV every 3 weeks. Before joining, patients have had a TURBT (a bladder tumor biopsy/removal procedure) and staging scans. The study tracks how long patients keep their bladder without cancer returning, whether they later need bladder removal (salvage cystectomy), survival outcomes, side effects, and patient-reported symptoms. Blood, urine, and tissue samples will be stored for future research. After finishing treatment, participants are followed regularly for up to 5 years.

This study may be appropriate for those with: Newly Diagnosed Cancer

Adjuvant Radiation for Pleural Mesothelioma

This randomized Phase 3 study compared two approaches for treating stage I-IIIA malignant pleural mesothelioma that is suitable for pleurectomy/decortication (P/D). All patients received surgery to remove visible tumor and standard chemotherapy (pemetrexed with cisplatin or carboplatin). Half of the patients were randomly assigned to also get adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT), a targeted form of radiation to the chest lining, while the other half received no additional radiation. The main goal was to see if adding IMPRINT improves overall survival. Secondary goals included measuring local control, spread to distant sites, progression-free survival, treatment-related side effects, and quality of life. The study also planned exploratory analyses of staging accuracy, surgical outcomes, biomarkers, and radiation dose effects. After treatment, patients were followed frequently for the first 2 years and then every 6 months for up to 5 years. The trial was terminated early, so only limited outcome data were available.

This study may be appropriate for those with: Newly Diagnosed Cancer

AMXT1501 and DFMO With Standard Care

This open-label Phase 1b/2 study tests two oral drugs, AMXT 1501 and DFMO, given together with standard treatments in people with advanced ER+ / HER2- breast cancer or with unresectable or metastatic cutaneous melanoma. AMXT 1501 blocks tumor uptake of polyamines and DFMO lowers polyamine production; together they aim to reduce tumor-supporting molecules and possibly improve responses to standard therapy. In the breast cancer group the combo is given with fulvestrant and capivasertib. In the melanoma group the combo is given with pembrolizumab. The Phase 1b part uses a small dose-escalation plan to find a safe dose for Phase 2. The Phase 2 part will look for signs the treatment controls or shrinks tumors using standard tumor response rules. The study also checks drug levels in blood, changes in tumor tissue and immune genes, and overall safety. About 92 patients may be enrolled across the two groups. Participants will have screening tests, regular clinic visits each treatment cycle (28 days), imaging to measure response, and follow-up visits.

This study may be appropriate for those with: Metastatic Cancer

IMGN151 in Gynecologic Cancers

This Phase 1b study tests IMGN151, an investigational cancer drug, in adults with gynecologic cancers. About 377 people will join at about 50 sites. Participants are placed into treatment groups: IMGN151 given with carboplatin, with olaparib, with bevacizumab, or as IMGN151 alone. The main goals are to find dose‑limiting toxicities and to assess safety and side effects over the study period, and to look for early signs that tumors respond (shrink or stop growing). Participants must have good performance status, most need at least one measurable tumor by scan, and must meet timing rules for prior treatments. People with certain ovarian tumor types, prior FRα‑targeting therapy, large prior radiation to the marrow, or other significant medical issues are not allowed. The study lasts about 3 years overall. Participants will come for regular clinic visits for infusions, blood tests, and scans and will stay on treatment until disease progression, unacceptable side effects, or other reasons to stop.

This study may be appropriate for those with: Newly Diagnosed Cancer

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

This study may be appropriate for those with: Newly Diagnosed Cancer

Study on ABBV-383 for Relapsed or Refractory Multiple Myeloma

This study focuses on testing the safety and dose optimization of a new drug, ABBV-383, for adults with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers are trying to find the best way to use this drug by looking at different dose levels. They will monitor participants for adverse effects like cytokine release syndrome, which can cause symptoms like fever and low blood pressure. The study includes three groups, each with different dosing plans. Around 180 participants will be treated with ABBV-383 as an IV infusion every 28 days for about three years. Throughout the study, participants will undergo medical checks and fill out questionnaires to track their health and any side effects.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Testing Venetoclax for Relapsed Hairy Cell Leukemia

This study is investigating the effectiveness of the drug venetoclax in patients whose hairy cell leukemia has returned after initial treatment. Venetoclax works by blocking a protein necessary for cancer cell survival, potentially reducing cancer growth. Participants will take venetoclax daily in cycles, and their response will be monitored through medical tests, including blood samples and imaging scans. The study aims to measure the overall response rate, complete remission, and any side effects. Eligible participants are those who have not had prior venetoclax treatment and meet specific health criteria. People with certain conditions or allergies should not participate. The study will follow participants for 30 days after their last medication dose to assess outcomes.

This study may be appropriate for those with: Relapsed / Refractory Cancer

A Study of LP-118 in Patients With Advanced Tumors

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects. The study has a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b). Secondary objectives of the study are to evaluate preliminary efficacy regarding the effect of LP-118 on objective response rate (ORR) using disease specific response criteria, progression-free survival (PFS), and duration of response (DOR), and overall survival (OS) in adult subjects with relapsed/refractory blood cancers.

This study may be appropriate for those with: Relapsed / Refractory Cancer